Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TIBOTEC PHARMACEUTICALS

Home Clinical Trial Sponsors and OrganizationsTIBOTEC PHARMACEUTICALS

TIBOTEC PHARMACEUTICALS

ACTIVE

1020 Stony Hill Rd Ste 300, Yardley, Pennsylvania, United StatesSubsidiary

Part of 强生

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

67

65 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

27

40.3%

Phase 3

1

1.5%

Trial Status Distribution

Active, not recruiting

64

95.5%

Completed

2

3.0%

Not yet recruiting

1

1.5%

Clinical Trials

Trials sponsored by this organization (67)

TMC114-TiDP29-C228 – A safety study to evaluate the antiviral activity of darunavir (DRV) in combination with ritonavir (rtv) in HIV 1 infected children from 3 years to below 6 years of age

Active, not recruiting

Feb 201424 participants

A safety study to evaluate the antiviral activity of darunavir in combination with ritonavir in HIV 1 infected adolescents between 12 and 18 years of age who have not received previous treatment with antiretroviral drugs

Active, not recruiting

Mar 201212 participants

A pediatric trial to provide dose recommendation of TMC114/rtv in HIV-1 infected children and adolescents

Active, not recruiting

Mar 201280 participants

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFa-2a and Ribavirin in Chronic Hepatitis C Patients who Were Null or Partial Responders to Prior PegINFa-2a and Ribavirin Therapy

Active, not recruiting

Feb 2012763 participants

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFa-2a and Ribavirin in Chronic Hepatitis C Patients who Were Null or Partial Responders to Prior PegINFa-2a and Ribavirin Therapy

Active, not recruiting

Feb 2012763 participants

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFa-2a and Ribavirin in Chronic Hepatitis C Patients who Were Null or Partial Responders to Prior PegINFa-2a and Ribavirin Therapy

Active, not recruiting

Dec 2011744 participants

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINF?-2a and Ribavirin in Chronic Hep C Patients who Were Null or Partial Responders to Prior PegINF?-2a and Ribavirin Therapy.

Active, not recruiting

Nov 2011763 participants

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFa-2a and Ribavirin in Chronic Hep C Patients who Were Null orPartial Responders to Prior PegINFa-2a and Ribavirin Therapy.

Active, not recruiting

Nov 2011744 participants

Page 1 of 9

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials67
Approvals
News

Back to Organizations